重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌的疗效观察

目的研究重组人血管内皮抑制素（恩度）联合化疗治疗晚期非小细胞肺癌的临床疗效和毒副反应。方法27例非小细胞肺癌均为ⅢB-Ⅳ期患者，初治或复治，采用化疗联合恩度治疗，化疗采用常规一、二线方案，恩度15mg／次，每日1次，连续14天，每3周重复使用，每例患者至少接受2周期恩度治疗。病理类型分别为：腺癌13例，鳞癌11例，其它类型3例；恩度联合一线化疗者11例，恩度联合二线化疗者10例，恩度联合三线及以上治疗者6例。结果27倒有效率（CR＋PR）为22．2％，临床受益率（CBR）为85．7％；中位TTP4．2个月。恩度联合一线化疗者11例，中位TTP6．5个月；恩度联合二线化疗者10例，中位TTP23个月；恩度联合三线及以上治疗者6例，中住TTP1．5个月。毒副反应主要为心脏毒副反应，包括心悸、胸闷、早搏等。其他为化疗相关的毒副反应如骨髓抑制和Ⅰ～Ⅱ度的胃肠道及外周神经毒性。结论恩度联合化疗安全有效，耐受性好，毒副反应以Ⅰ～Ⅱ度为主，初治与复治均有效果，一线使用获益更大。     

重组人血管内皮抑制素注射液联合NP方案治疗晚期非小细胞肺癌的疗效观察

目的观察了解重组人血管内皮抑制素注射液（恩度）联合NP方案治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法37例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。恩度联合顺铂治疗2～4个周期后评价疗效。结果37例患者中CR4例,PR15例,有效率51．4％（19／37）。中位TTP为6．8个月,1年生存率为43．2％。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论恩度联合NP方案治疗老年晚期NSCLC有较好疗效,可明显改善患者生存质量,毒副反应轻,易于耐受。     

恩度联合同步热放化疗治疗中晚期宫颈癌的临床观察

目的:探讨恩度联合同步热放化疗治疗中晚期宫颈癌的临床疗效。方法:选取2014年02月至2016年05月我院收治的中晚期宫颈鳞癌及宫颈腺癌的患者66例,按照随机的方式分为对照组和实验组两组,对照组34例为同步放化疗联合热疗,实验组32例为恩度联合同步热放化疗,两组的热放化疗相同:放疗为全盆腔放疗4600c Gy/23f,化疗为每周1次顺铂20mg/m2静脉滴注,共4周。热疗采用区域深部热疗,每周2次,实验组在放疗开始每天1次恩度7.5mg/m2静脉滴注,共4周。结果:实验组和对照组的客观有效率为87.6%和61.8%,两组差异有统计学意义(P0.05);实验组和对照组的疾病控制率分别为97.0%和91.2%,两组差异无统计学意义(P0.05)。结论:恩度联合热放化疗治疗中晚期宫颈癌安全有效,值得临床推广。     

恩度联合INCA化疗方案治疗老年性晚期非小细胞肺癌效果分析

目的评价恩度（重组人血管内皮抑素,endostar,YH一16）联合GP（吉西他滨＋顺铂）治疗老年性晚期非小细胞肺癌（NSCLC）的有效性和安全性。方法72例老年性晚期NSCLC患者被随机分为两组,试验组（40例）应用YH一16联合GP方案,对照组（32例）予以常规GP方案化疗。两组患者均至少完成2个周期。结果试验组有效率（RR）为42．5％,临床获益率（CBR）为80．0％;对照组有效率（RR）28．13％,临床获益率（CBR）为56．2％。两组毒副反应相似,患者的主要毒副反应有恶心、呕吐、白细胞减少等。结论恩度联合GP方案治疗老年性晚期NSCLC是一种有效、安全的方案。     

放疗同期DX方案化疗治疗晚期食管癌临床研究

目的探讨同期放化疗治疗局部晚期食管癌的临床疗效及毒性反应.方法将2002年1月～2004年6月56例局部晚期食管癌患者随机分为单纯放疗组和同期放化疗组,每组28例,两组放疗均采用常规分割放射治疗,总剂量60～70Gy,化疗采用Dx方案[多西紫杉醇37.5mg/m2,静脉滴注,第1、8d,希罗达2.0g/(m2·d),分2次口服,连用2w].21d化疗1周期,化疗共4个周期,与放疗同期进行2个周期,放疗结束后2个周期.结果同期放化疗组1、2,3年生存率分别为57.1%(16/28),42.8%(12/28),35.7%(10/28);单纯放疗组的1、2,3年生存率分别为53.4%(15/28),39.3%(11/28),14.3%(4/28).结论同期放化疗对局部晚期食管癌具有协同作用,可提高疗效,但毒副反应增加,值得进一步研究.     

NP方案化疗并射频透热治疗晚期非小细胞肺癌近期疗效观察

目的观察盖诺（长春瑞宾）加顺铂方案化疗并射频透热治疗晚期非小细胞肺癌（NSCLC）的疗效和毒副反应。方法给予患者深静脉置管,盖诺25mg／m^2,加入生理盐水100ml中静滴10min,第1、8天,顺铂40mg,连续静滴3d,每21d为1个周期,2～3个周期结束评价疗效。射频透热治疗于每个化疗周期第1d即开始,每周2次,连做4次。结果NP方案化疗结合射频透热治疗晚期NSCLC,总有效率达51．5％,毒性反应主要是化疗引起的副作用,以自细胞减少最常见,其次是恶心、呕吐等。热疗的副作用主要表现为出汗,但均能耐受。结论NP方案化疗并射频透热治疗对晚期NSCLC有较好的疗效,且初治疗效优于复治,鳞癌疗效优于腺癌。治疗期间未出现严重或不可治的毒性反应。     

局部中晚期食管癌放疗联合雷替曲塞及顺铂化疗的临床观察

目的 观察雷替曲塞联合顺铂同步放疗治疗局部中晚期食管癌的近期疗效和毒副作用。方法 选择40例经病理证实为鳞癌的中晚期食管癌患者。全部患者采用6MV-X射线适形放射治疗,总剂量60Gy,2Gy/次,每周5次。化疗在放疗的第1天开始,雷替曲塞3mg/m²;每三周为一周期,每个周期第一天,第一至第三天,顺铂25mg/(m²·d),按照RECIST评价标准评定疗效和不良反应。结果 40例总有效31例(77.5%),其中CR 13例(32.5%),PR 18例(45.0%),SD 7例(17.5%),PD 2例(5.0%)。主要毒副反应表现为急性放射性食管炎、消化道反应、骨髓抑制,3~4度少见,未见明显肝肾毒性。结论 雷替曲塞联合顺铂同步放疗治疗局部中晚期食管癌疗效较好,毒副反应能耐受,值得临床推广。     

多西紫杉醇联合长春瑞滨治疗转移性乳腺癌的疗效分析

[目的]研究多西紫杉醇（TAT）、长春瑞滨（NVB）联合方案在转移性乳腺癌治疗中的疗效及毒副反应.[方法]采用多西紫杉醇75 mg/m2,静滴,d 1,长春瑞滨25 mg/m2,静滴,d 1、8,每21 d为1周期,完成2周期后开始评价疗效,随访7～24个月.[结果]完全缓解（CR）31.25%（10/32）,部分缓解（PR）43.75%（14/32）,稳定（SD）25.0%（8/32）.无疾病进展者,总有效率（ORR）为（CR＋PR）75.0%（24/32）.毒性反应主要为白细胞降低Ⅲ-Ⅳ度为75.0%,胃肠道反应轻微.[结论]TAT联合NVB（TN方案）治疗转移性乳腺癌疗效显著,不良反应可耐受.     

多西他赛联合FOLFOX_6对晚期胃癌疗效观察

目的：评价多西他赛联合FOLFOX6方案治疗晚期胃癌的疗效及毒副反应。方法：对无法手术的36例Ⅲ～Ⅳ期胃癌患者,应用多西他赛75mg/m2,d1,奥沙利铂（85mg/m2,d1）,亚叶酸钙（200mg/m2,静脉注射,d1）、2,5-FU400mg/m2,静脉注射,d1、2,5-FU2400mg/m2,CIV,46h,21d为1个周期。结果：有效率58.3%（21/36）,中位TTP时间6.5个月,1年生存率52.8%,生活质量改善69.4%。化疗不良反应主要为骨髓抑制及周围神经毒性,发生率分别为69.4%、55.6%,多为Ⅰ～Ⅱ度。结论：多西他赛联合FOLFOX6治疗晚期胃癌疗效好,不良反应可耐受。     

102例晚期食管癌患者紫杉醇联合顺铂治疗观察

目的观察紫杉醇（PTX）联合顺铂（DDP）组成的TP方案治疗晚期食管癌的近期疗效和毒副反应。方法102例晚期食管癌患者,给予TP方案化疗：PTX175mg／m^2,静脉滴注,d1;DDP40mg／m^2,静脉滴注,d1～3,21d为一个周期。结果102例患者总有效率37．3％,稳定率54．9％,临床获益率达92．2％;毒副反应主要为剂量限制性毒性,表现为Ⅲ～Ⅳ度骨髓抑制（17．6％）。结论TP方案治疗晚期食管癌有效率较高,毒副反应可耐受。     

吉非替尼联合择期放疗治疗晚期非小细胞肺癌的临床研究

目的 观察吉非替尼联合择期放疗治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法 13例晚期NSCLC,应用吉非替尼治疗,对10例吉非替尼治疗获益的患者,根据患者及家属意愿分为联合组和对照组,每组5例,联合组联合放疗,对照组继续单独应用吉非替尼治疗直至病情进展.结果 到随访截止日期,全部患者1年生存率达53.8%(7/13),2年生存率达46.2%(6/13).联合组和对照组的中位无进展生存期(PFS)分别为24个月和8个月(P=0.0019),中位总生存期(OS)分别为32个月和10个月(P=0.0062).不良反应主要为皮疹和腹泻.无症状性肺纤维化3例.结论 吉非替尼联合择期放疗治疗晚期NSCLC可以显著延长PFS和OS,不良反应可以耐受,是NSCLC规范化治疗和个体化治疗的合理选择.

Abstract：

Objective To study the effect and toxicity ofgefitinib combined with selected radiotherapy in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Methods From March 2006 to February 2009,10 of 13 advanced NSCLC patients who got benefit from gefitinib were enrolled to treatment group (gefitinib concurrent selected radiotherapy) and control group (gefitinib only), with 5 cases in each group. The response was evaluated as progression free survival (PFS) and overall survival (OS).Results No patient got complete remission (CR). Ten of 13 patients got partial remission (PR) and stable disease (SD). The 1 year and 2 years survival rate was 53.8%(7/13) and 46.2%(6/13) respectively. The median PFS in treatment group and control group was 24 months and 8 months respectively(P= 0.0019). The median OS was 32 months and 10 months respectively (P= 0.0062). The main toxicities were reversible skin rash and diarrhea,and 3 patients developed asymptomatic radiation pulmonary fibrosis. Conclusions Gefitinib combining with selected radiotherapy is effective and tolerated in patients with advanced NSCLC. It may prolong PFS and OS. It may be a rational choice for the standard and individualized treatment of NSCLC.     

A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer

The Radiation Therapy Oncology Group reported a maximum tolerated dose of 74 Gy for patients with non-small cell lung cancer (NSCLC); however, it was unclear whether this dose could be safely administered to Asian patients due to differences in their physique compared to Western patients. We therefore conducted a modified Phase I trial to determine whether 70 Gy could be safely delivered to Chinese patients with NSCLC undergoing 3D-conformal radiation therapy (3D-CRT) with concurrent chemotherapy. Previously untreated NSCLC patients received 3D-CRT (2 Gy/day, 5 fractions per week). Three dose levels were examined: 62, 66 and 70 Gy. Two cycles of concurrent chemotherapy (vinorelbine and carboplatin) were started on the first day of radiation therapy. Dose-limiting toxicity (DLT) was defined as severe or life-threatening side effects that altered the continued implementation of chemoradiotherapy. Among the 19 patients recruited in this study, most of the haematologic and non-haematologic toxicities were mild to moderate and clinically manageable. Only one patient, in the 70 Gy cohort, experienced a DLT of Grade 3 radiation-induced pneumonia. The overall response rate was 77.8% (14/18). The median progression-free survival (PFS) was 12 months, and the 1-year PFS was 37.6%. Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. A further evaluation of this regimen in a prospective Phase II trial is ongoing.     

Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer

The purpose of this study was to assess the efficacy of ¹⁸F-fluoro-2-deoxy-glucose uptake positron emission tomography (FDG-PET) for the prediction of outcome in definitive chemoradiotherapy (CRT) for esophageal cancer. We enrolled 56 patients with esophageal cancer treated with definitive CRT and examined by FDG-PET before treatment. We examined the correlation of the maximum standardized uptake value (SUVmax) in FDG-PET of the primary tumor with overall survival (OS), progression-free survival (PFS), local control (LC) and response of the primary tumor. After definitive CRT, 30 patients had a clinical complete response (CR), making the CR rate 54%. For all 56 patients, the 2-year OS rate, PFS rate and LC rates were 64%, 38% and 51%, respectively. We divided the patients into two groups according to SUVmax: SUVmax < 10 (low-SUV) and ≥10 (high-SUV). The 2-year OS rates in the low- and high-SUV groups were 100% and 41%, the PFS rates were 73% and 19%, the LC rates were 71% and 39%, and the CR rates were 100% and 32%, respectively. A univariate analysis revealed significant differences between the low- and high-SUV group in OS, PFS, LC and response (P = 0.0005, 0.0002, 0.048, and <0.0001, respectively). SUVmax and T stage were significantly associated with OS, PFS, LC and response. A multivariate analysis showed significant differences between the SUVmax <10 and ≥10 groups in overall survival and response (P < 0.05). Our result suggests that the SUVmax in FDG-PET of the primary tumor before treatment may have prognostic value for esophageal cancer.     

Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors

Cisplatin-based concurrent chemoradiotherapy (CCRT) is a standard treatment for cervical cancer, but nedaplatin-based CCRT is not routinely administered. We evaluated the efficacy and safety of nedaplatin-based CCRT (35 mg/m² weekly) and analyzed prognostic factors for survival among 52 patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IB2–IVA cervical cancer treated from 1999 to 2009. Patients were treated with a combination of external beam radiotherapy of 40–56 Gy (in 20–28 fractions) and 13.6–28.8 Gy (in 2–4 fractions) of high-dose-rate (HDR) intracavitary brachytherapy or 18 Gy (in 3 fractions) of HDR interstitial brachytherapy. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. Acute and late toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. The median follow-up period was 52 months. The median patient age was 63 years. The 5-year OS, PFS and LC rates were 78%, 57% and 73%, respectively. Multivariate analysis showed that histologic type, maximum tumor diameter, and pretreatment hemoglobin level were independent risk factors for PFS. Regarding adverse effects, 24 patients (46%) had acute Grade 3–4 leukopenia and 5 (10%) had late Grade 3 gastrointestinal toxicities. No patient experienced renal toxicity. Nedaplatin-based CCRT for FIGO Stage IB2–IVA cervical cancer was efficacious and safe, with no renal toxicity. Histologic type, maximum tumor diameter, and pretreatment hemoglobin level were statistically significant prognostic factors for PFS.     

Prognostic Value of the Geriatric Nutritional Risk Index in Patients Exceeding 70 Years Old with Esophageal Squamous Cell Carcinoma

Abstract

To investigate the prognostic value of the Geriatric Nutritional Risk Index (GNRI) in esophageal squamous cell carcinoma (ESCC) patients treated with radiotherapy (RT) or definitive concurrent chemoradiotherapy (dCRT). Fifty-two ESCC patients were included from July 2014 to December 2018. RT was delivered at a dose of 1.8–2.0?Gy per day to a total dose of 50–60?Gy. Tumor response was assessed using the RECIST 1.1 system. Overall survival (OS) and progression-free survival (PFS) were calculated and compared with the Kaplan–Meier method. Multivariate analysis of predictive factors of response and survival was performed using a logistic regression and a Cox model, respectively. In multivariate analysis, GNRI score (HR 0.278, P?=?0.036) was the only independent prognostic factor for tumor response. As for survival outcomes, GNRI score (OS: HR 0.505, P?=?0.028; PFS: HR 0.583, P?=?0.045) and treatment modality (OS: HR 0.356, P?=?0.015; PFS: HR 0.392, P?=?0.0014) were both independent prognostic factors for better OS and PFS. Additionally, there was no correlation between GNRI score and treatment modality (Spearman’s ρ?=?0.200; P?=?0.154). In conclusion, routine use of the GNRI criteria may help in the risk stratification of elderly patients undergoing RT/dCRT. The dCRT treatment could provide survival benefits for elderly ESCC patients.     

Treatment outcomes of definitive chemoradiotherapy for patients with hypopharyngeal cancer

We analyzed the efficacy of definitive chemoradiotherapy (CRT) for patients with hypopharyngeal cancer (HPC). Subjects comprised 97 patients who were treated with definitive CRT from 1990 to 2006. Sixty-one patients (62.9%) with resectable disease who aimed to preserve the larynx received induction chemotherapy (ICT), whereas 36 patients (37.1%) with resectable disease who refused an operation or who had unresectable disease received primary alternating CRT or concurrent CRT (non-ICT). The median dose to the primary lesion was 66 Gy. The median follow-up time was 77 months. The 5-year rates of overall survival (OS), progression-free survival (PFS), local control (LC), and laryngeal preservation were 68.7%, 57.5%, 79.1%, and 70.3%, respectively. The T-stage was a significant prognostic factor in terms of OS, PFS and LC in both univariate and multivariate analyses. The 5-year rates of PFS were 45.4% for the ICT group and 81.9% for the non-ICT group. The difference between these groups was significant with univariate analysis (P = 0.006). Acute toxicity of Grade 3 to 4 was observed in 34 patients (35.1%). Grade 3 dysphagia occurred in 20 patients (20.6%). Twenty-nine (29.8%) of 44 patients with second primary cancer had esophageal cancer. Seventeen of 29 patients had manageable superficial esophageal cancer. The clinical efficacy of definitive CRT for HPC is thought to be promising in terms of not only organ preservation but also disease control. Second primary cancer may have a clinical impact on the outcome for HPC patients, and special care should be taken when screening at follow-up.     

培美曲塞联合顺铂一线治疗晚期非小细胞肺癌临床研究

目的研究培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床疗效及不良反应。方法 52例晚期非小细胞肺癌患者,给予培美曲塞联合顺铂方案全身化疗。培美曲塞:500mg/m2,第1天静脉滴注,顺铂:75mg/m2,第1天静脉滴注,每21天为1个周期,连用2～6个周期。结果 52例患者中非鳞癌41例,鳞癌11例,完全缓解(CR)1例,部分缓解(PR)18例,稳定(SD)13例,进展(PD)20例,总有效率(CR+PR)为36.5%,疾病控制率(CR+PR+SD)为61.5%;不同年龄、性别、临床分期、病理类型之间在有效率和疾病控制率方面差异无统计学意义(P>0.05)。所有患者PFS为4.8个月,非鳞癌患者为5.1个月,鳞癌患者为4.4个月,但两者之间差异无统计学意义(P>0.05);不良反应主要是消化道反应和骨髓抑制,多为Ⅰ～Ⅱ级。结论培美曲塞联合联合顺铂是一线治疗晚期非小细胞肺癌安全、有效的治疗方案。     

NSCLC患者Tα1维持治疗与T、B、NK细胞免疫功能联合测定的临床研究

目的研究NSCLC患者Tα1维持治疗与T、B、NK细胞免疫功能联合测定的临床意义,方法对60例非小细胞肺癌（NSCLC）患者化疗后,随机分为两组,维持组30例给予胸腺肽α1（Tα1）维持治疗3～6个月,1.6mg,每周两次,对照组30例只给予观察;所有患者治疗前及治疗后分别测定CD3/HLA-DR,CD4/HLA-DR/CD8,CD3/CD16＋CD56,CD25/CD3/CD19,对比用Tα1维持组与非Tα1维持组两组的PFS（无进展生存期）,中位生存期（MST）,生活质量（KPS评分）。总生存时间（OS）。结果本组患者化疗前后细胞免疫功能表明;化疗后CD3~＋、CD4~＋细胞升高,CD8~＋细胞下降,但与化疗前无明显差异（P〉0.05）。CD4~＋/CD8~＋则显著升高,NK细胞降低,B淋巴细胞增高,与化疗前均有统计学意义（P〈0.05）。胸腺肽α1治疗组（A组）和对照组（B组）治疗后CD3~＋、CD4~＋、CD4~＋/CD8~＋、B NK细胞活性值均提高,P〈0.05,CD8值无明显变化。细胞免疫功能与临床参数的关系,Ⅲb期与Ⅳ期相比较P〈0.05,≤55岁组与〉55岁组比较P〈0.05,可见临床分期越晚,年龄越大细胞免疫功能越低下。Tα1维持治疗组近期有效率（CR,PR及ORR）及PFS,MST,与对照组相比均有统计学意义（P〈0.05）,1年0S两组没有统计学意义,P〉0.05。两组3,4度毒副反应没有明显差异,治疗组较对照组明显提高KPS,18比5,体重也增加,17比6,P〈0.01有显著的统计学差异。结论胸腺肽α维持治疗可使晚期非小细胞肺癌患者化疗后的免疫功能提高,增强抗病能力,减弱抑制肿瘤的能力,延长生存时间,毒副反应轻,生活质量提高,值得进一步研究推广。     

Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer

Preoperative chemoradiotherapy with capecitabine or 5-fluorouracil is a standard treatment for locally advanced rectal cancer (LARC). S-1, a prodrug of 5-fluorouracil, is a candidate for this chemoradiotherapy regimen in Japan; however, treatment outcomes after S-1 treatment alone are not clear. This study aimed to assess the efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for LARC. We retrospectively evaluated 54 LARC patients who underwent preoperative chemoradiotherapy with S-1 alone in our institution between 2005 and 2017. The clinical tumor stage was cT2–3 in 31 patients and cT4 in 23 patients, and lymph node metastases were clinically evident in 31 patients. S-1, at a dose of 80 mg/m²/day, was orally administered during radiotherapy. A total dose of 45–50.4 Gy was delivered in 25–28 fractions (median: 50.4 Gy). Surgical resections were scheduled 6–10 weeks after chemoradiotherapy completion. The 3- and 5-year overall survival rates were 92.4 and 72.8%, respectively, with a median follow-up time of 51 months. The 3- and 5-year local control rates were 96.2 and 85.9%, respectively. A pathological complete response was observed in 7 patients (13.0%) at the time of surgery. Ten patients (18.5%) had grade 3 acute toxicities and 5 patients (9.3%) had grade 3 late toxicities. No grade 4 or 5 toxicities were observed. Preoperative chemoradiotherapy with S-1 alone followed by total mesorectal excision resulted in a low incidence of toxicities and comparable clinical results. Therefore, S-1 alone can be a treatment option for preoperative chemoradiotherapy in LARC patients.     

贝伐单抗联合化疗治疗晚期非小细胞肺癌的有效性评价

目的评价贝伐单抗(15mg/kg)联合化疗治疗晚期非小细胞肺癌患者的有效性。方法通过检索PubMed和Cochrane Library数据库,收集了四个随机对照临床试验进行meta分析,有效性的评价指标包括疾病无进展生存时间(PFS)和总生存时间(OS)。结果与对照组相比,贝伐单抗组的患者的疾病进展风险比为0.709(P<0.001),死亡风险比为0.804(P=0.002)。结论对于晚期非小细胞肺癌,采用贝伐单抗(15mg/kg)联合化疗的治疗方法会显著提高患者的PFS和OS。